Funding agencies: The study was cofunded by Nottingham University Hospitals (NUH) Special Trustees.
Version of Record online: 12 APR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 9, pages 1633–1638, 1 August 2011
How to Cite
Schwarz, S. T., Rittman, T., Gontu, V., Morgan, P. S., Bajaj, N. and Auer, D. P. (2011), T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov. Disord., 26: 1633–1638. doi: 10.1002/mds.23722
Relevant conflicts of interest/financial disclosures: Dr. Nin Bajaj has received honoraria for advisory work with Teva, GSK, UCB, and Genus and has received grants from GE Healthcare.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 9 AUG 2011
- Version of Record online: 12 APR 2011
- Manuscript Accepted: 24 FEB 2011
- Manuscript Revised: 11 FEB 2011
- Manuscript Received: 20 JUL 2010
Vol. 27, Issue 2, 335, Version of Record online: 6 FEB 2012
- Parkinson's disease;
- magnetic resonance imaging;
Depigmentation of the substantia nigra is a conspicuous pathological feature of Parkinson's disease and related to a loss of neuromelanin. Similar to melanin, neuromelanin has paramagnetic properties resulting in signal increase on specific T1-weighted magnetic resonance imaging. The aim of this study was to assess signal changes in the substantia nigra in patients with Parkinson's disease using an optimized neuromelanin-sensitive T1 scan. Ten patients with Parkinson's disease and 12 matched controls underwent high-resolution T1-weighted magnetic resonance imaging with magnetization transfer effect at 3T. The size and signal intensity of the substantia nigra pars compacta were determined as the number of pixels with signal intensity higher than background signal intensity + 3 standard deviations and regional contrast ratio. Patients were subclassified as early stage (n = 6) and late stage (n = 4) using the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr Parkinson's disease staging scale. The T1 hyperintense area in the substantia nigra was substantially smaller in patients compared with controls (−60%, P < .01), and contrast was reduced (−3%, P < .05). Size reduction was even more pronounced in more advanced disease (−78%) than in early-stage disease (−47%). We present preliminary findings using a modified T1-weighted magnetic resonance imaging technique showing stage-dependent substantia nigra signal reduction in Parkinson's disease as a putative marker of neuromelanin loss. Our data suggest that reduction in the size of neuromelanin-rich substantia nigra correlates well with postmortem observations of dopaminergic neuron loss. Further validation of our results could potentially lead to development of a new biomarker of disease progression in Parkinson's disease. © 2011 Movement Disorder Society